Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
Wheeler DC, Stefánsson BV, Jongs N, et al.
Lancet Diabetes Endocrinol. 2021;9(1):22-31
Leggi